pharma · Basel, CH

Roche

Account opportunity

Not established

Relationship

Active signals

Trials as sponsor

Why this account matters

Roche

New trial — A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

New trialNCT03178552

63/100

Opportunity

Commercial fit12/25

Clinical timing20/20

Biomarker need10/20

Relationship2/10

Signal strength9/10

Account value7/10

Urgency3/5

New phase 2_3 trial NCT03178552 posted by Hoffmann-La Roche: "A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)". New trial on a phase 2_3 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 5 days ago.

ConfidenceHigh · 95%clinical development · translational medicine · clinical operations

Draft outreach Review

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

Roche

New trial — A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

New trialNCT06793215

52/100

Opportunity

Commercial fit6/25

Clinical timing18/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value7/10

Urgency5/5

New phase 3 trial NCT06793215 posted by Hoffmann-La Roche: "A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated today.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Roche

New trial — A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

New trialNCT07541170

48/100

Opportunity

Commercial fit6/25

Clinical timing18/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value7/10

Urgency1/5

New phase 3 trial NCT07541170 posted by Hoffmann-La Roche: "A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 29 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Roche

New trial — A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

New trialNCT04929223

44/100

Opportunity

Commercial fit5/25

Clinical timing20/20

Biomarker need0/20

Relationship2/10

Signal strength9/10

Account value7/10

Urgency1/5

New phase 1 trial NCT04929223 posted by Hoffmann-La Roche: "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 22 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

Trial	Phase	Testing language
NCT06793215 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer	phase 3	mol. elig.
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)	phase 2 3	ctDNA
NCT04929223 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	phase 1	—
NCT07541170 A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)	phase 3	mol. elig.